Physician profile
Jorge E Rangel
NPI 1982672796
$4,311.50
in general payments reported to CMS, 2019-2025
14 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.17 · 2020: $53.16 · 2021: $663 · 2022: $631 · 2023: $843 · 2024: $966 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,877.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,465.83 | 2019-2025 | Dovato, Rukobia, Apretude |
| Gilead Sciences, INC. | $1,198.78 | 2019-2025 | Biktarvy |
| Janssen Products, LP | $158.98 | 2020-2021 | |
| Amgen INC. | $85.68 | 2023-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $75.77 | 2024 | |
| Merck Sharp & Dohme LLC | $70.11 | 2021-2022 | |
| Hologic Sales and Service, LLC | $63.96 | 2024-2025 | Thinprep 2000 Processor, Aptima |
| Novartis Pharmaceuticals Corporation | $49.59 | 2024 | |
| Averitas Pharma INC. | $32.65 | 2025 | Qutenza |
| Lilly USA, LLC | $32.50 | 2024-2025 | Mounjaro, Zepbound |
| Emd Serono, INC. | $28.74 | 2024 | |
| Phadia US INC. | $27.22 | 2021-2022 | |
| Therapeuticsmd, INC. | $17.75 | 2021 | |
| Napo Pharmaceuticals INC | $3.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Rangel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.